In vivo Serum Enabled Production of Ultrafine Nanotherapeutics for Cancer Treatment.

ABSTRACT: Systemic delivery of hydrophobic anti-cancer drugs with nanocarriers, particularly for drug-resistant and metastatic cancer, remain a challenge because of the difficulty to achieve high drug loading, while maintaining a small hydrodynamic size and colloid stability in blood to ensure delivery of an efficacious amount of drug to tumor cells. Here we introduce a new approach to address this challenge. In this approach, nanofibers of larger size with good drug loading capacity are first constructed by a self-assembly process, and upon intravascular injection and interacting with serum proteins in vivo, these nanofibers break down into ultra-fine nanoparticles of smaller size that inherit the drug loading property from their parent nanofibers. We demonstrate the efficacy of this approach with

SUBMITTER: Mu Q 

PROVIDER: S-EPMC7944405 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature